TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
Frontiers | Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?
IJMS | Free Full-Text | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors | HTML
Systematic identification of mutations and copy number alterations associated with cancer patient prognosis | eLife
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
Implications of driver genes associated with a high tumor mutation burden identified using next‑generation sequencing on immunotherapy in hepatocellular carcinoma
Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignancies | medRxiv
Five‐year overall survival rate in patients with oncomorphic and... | Download Scientific Diagram
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer | Accounts of Chemical Research
The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis - Journal of Biological Chemistry
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia | Haematologica
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - ScienceDirect
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
Disarming mutant p53 oncogenic function - ScienceDirect
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | PNAS
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm | ACS Chemical Biology
High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer | Experimental & Molecular Medicine
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia | Haematologica
